https://www.selleckchem.com/pr....oducts/enarodustat.h
At a median follow-up of 24 months, all patients had progressed and 6 patients were alive. Median treatment duration was 11.0 weeks (95%CI 6.0-15.9) in the regorafenib group and 6.3 weeks (95%CI 3.9-7. in the placebo group (p=0.002). Fourteen of 33 patients (42%) in the regorafenib group had a dose reduction. Stable disease rates were 74% (95%CI 59-9 in the regorafenib group and 34% with placebo (95%CI 18-51; p=0.002). Median PFS in the regorafenib group was 3.0 months (95%CI 2.3-4.9) and 1.5 months (95%CI 1.2-2. in the placeb
Like
Comment
Share
